Cargando…

Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Creta, Massimiliano, Celentano, Giuseppe, Napolitano, Luigi, La Rocca, Roberto, Capece, Marco, Califano, Gianluigi, Collà Ruvolo, Claudia, Mangiapia, Francesco, Morra, Simone, Turco, Carmine, Spirito, Lorenzo, Fusco, Ferdinando, Imbimbo, Ciro, Mirone, Vincenzo, Longo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923424/
https://www.ncbi.nlm.nih.gov/pubmed/33672461
http://dx.doi.org/10.3390/diagnostics11020351
_version_ 1783658899373555712
author Creta, Massimiliano
Celentano, Giuseppe
Napolitano, Luigi
La Rocca, Roberto
Capece, Marco
Califano, Gianluigi
Collà Ruvolo, Claudia
Mangiapia, Francesco
Morra, Simone
Turco, Carmine
Spirito, Lorenzo
Fusco, Ferdinando
Imbimbo, Ciro
Mirone, Vincenzo
Longo, Nicola
author_facet Creta, Massimiliano
Celentano, Giuseppe
Napolitano, Luigi
La Rocca, Roberto
Capece, Marco
Califano, Gianluigi
Collà Ruvolo, Claudia
Mangiapia, Francesco
Morra, Simone
Turco, Carmine
Spirito, Lorenzo
Fusco, Ferdinando
Imbimbo, Ciro
Mirone, Vincenzo
Longo, Nicola
author_sort Creta, Massimiliano
collection PubMed
description Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.
format Online
Article
Text
id pubmed-7923424
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79234242021-03-03 Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies Creta, Massimiliano Celentano, Giuseppe Napolitano, Luigi La Rocca, Roberto Capece, Marco Califano, Gianluigi Collà Ruvolo, Claudia Mangiapia, Francesco Morra, Simone Turco, Carmine Spirito, Lorenzo Fusco, Ferdinando Imbimbo, Ciro Mirone, Vincenzo Longo, Nicola Diagnostics (Basel) Review Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data. MDPI 2021-02-20 /pmc/articles/PMC7923424/ /pubmed/33672461 http://dx.doi.org/10.3390/diagnostics11020351 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Creta, Massimiliano
Celentano, Giuseppe
Napolitano, Luigi
La Rocca, Roberto
Capece, Marco
Califano, Gianluigi
Collà Ruvolo, Claudia
Mangiapia, Francesco
Morra, Simone
Turco, Carmine
Spirito, Lorenzo
Fusco, Ferdinando
Imbimbo, Ciro
Mirone, Vincenzo
Longo, Nicola
Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title_full Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title_fullStr Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title_full_unstemmed Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title_short Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
title_sort inhibition of androgen signalling improves the outcomes of therapies for bladder cancer: results from a systematic review of preclinical and clinical evidence and meta-analysis of clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923424/
https://www.ncbi.nlm.nih.gov/pubmed/33672461
http://dx.doi.org/10.3390/diagnostics11020351
work_keys_str_mv AT cretamassimiliano inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT celentanogiuseppe inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT napolitanoluigi inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT laroccaroberto inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT capecemarco inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT califanogianluigi inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT collaruvoloclaudia inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT mangiapiafrancesco inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT morrasimone inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT turcocarmine inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT spiritolorenzo inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT fuscoferdinando inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT imbimbociro inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT mironevincenzo inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies
AT longonicola inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies